Green Thumb Industries Will Benefit From Medical Cannabis Rescheduling

Green Thumb Industries reported strong Q1 2026 results, with revenue increasing and net income improving. The company also stands to benefit from the U.S. rescheduling of medical cannabis, a meaningful regulatory tailwind. GTBIF shares are already up 35% over the past year, reflecting improving fundamentals and a more favorable policy backdrop.

Analysis

Green Thumb Industries reported strong Q1 2026 results, with revenue increasing and net income improving. The company also stands to benefit from the U.S. rescheduling of medical cannabis, a meaningful regulatory tailwind. GTBIF shares are already up 35% over the past year, reflecting improving fundamentals and a more favorable policy backdrop.